<DOC>
	<DOCNO>NCT00809679</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy T-62 subject postherpetic neuralgia .</brief_summary>
	<brief_title>Analgesic Efficacy Safety Study T-62 Subjects With Postherpetic Neuralgia</brief_title>
	<detailed_description>Study K862-08-2002 multicenter , randomize , double-blind , placebo-controlled study assess analgesic efficacy safety T-62 subject postherpetic neuralgia ( PHN ) associate pain . Up 20 center United States participate trial . Two dose T-62 placebo evaluate parallel design . Approximately 130 subject enrol complete approximately 100 subject . Each subject complete 7-day Screening Period , 28-day Treatment Period , 14-day Post-Treatment Period . Each subject complete 8 clinic visit course study procedures assessment safety , efficacy , protocol compliance perform .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Inclusion criterion ( additional criterion apply ) : 1 . Diagnosis PHN make primary treating physician experience pain least 3 month heal herpes zoster rash . 2 . Subject general good health . 3 . Females must nonpregnant , nonlactating , practice acceptable method birth control surgically sterile postmenopausal . Double barrier method abstinence acceptable birth control method study . Exclusion Criteria ( additional criterion apply ) : 1 . Subject current acute disease unstable chronic disease post herpetic neuralgia . 2 . Subject clinically important history medical disorder ( particularly cardiovascular , neurological [ e.g. , diabetic neuropathy ] , respiratory , hepatobiliary system [ e.g. , Gilbert Syndrome ] ) would confound and/or interfere safety efficacy evaluation define protocol . 3 . Subject treat medical condition affect cardiac conduction . 4 . Subject 's plasma alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) , total bilirubin , alkaline phosphatase ( AP ) value within normal reference range . 5 . Subject history asthma require management reactive airway disease last year . 6 . Subject use unwilling/unable discontinue use ( A ) Lyrica® ( pregabalin ) , Cymbalta® ( duloxetine ) , Neurontin® ( gabapentin ) , topical lidocaine , topical capsaicin , medication specifically indicate ( i.e. , label ) treatment neuropathic pain , ( B ) anticonvulsant medication control post herpetic neuralgia . 7 . Subject currently require anticonvulsant medication control seizures .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Postherpetic neuralgia</keyword>
	<keyword>Varicella Zoster</keyword>
	<keyword>Shingles</keyword>
	<keyword>Neuropathic pain</keyword>
	<keyword>Analgesia</keyword>
	<keyword>Pain</keyword>
</DOC>